Hutchison MediPharma

Industry sector: Pharmaceuticals

Headquarters: Shanghai

China’s burgeoning pharmaceutical sector has produced few champions of innovation to date, but Hutchison MediPharma has bucked the trend. Established in 2002, the company is known for creating and developing compounds focused in particular on the treatment of cancer and autoimmune disorders. With two novel therapies – Theliatinib and Volitinib – entering Phase I trials this year and an established pipeline at various stages of development, the company stands out in this generic-dominated market for its modern approach and prioritisation of independent R&D.